Retatrutide (LY3437943): Research, Mechanism & Evidence

Overview

This page is the navigation center of the retatrutide cluster. It situates the compound, shows what class of evidence exists, and points to the six supporting pages. It is not the full definition of the peptide, not a systematic review, and not a press-release digest.

It also does not document a Peptra material lot or interpret a certificate of analysis. For chemical identity and investigational status, start with what retatrutide is. For receptors, see how it works. The trial program and the current TRIUMPH evidence state have their own pages.

Current research status

Those status claims are easier to read if four layers that generic summaries often collapse are kept apart.

• FDA status: no approval. A positive clinical phase is not an authorization.^13,14
• ClinicalTrials.gov status: each protocol has its own registry status. As of this review, TRIUMPH-1 is listed as Completed; TRIUMPH-2, TRIUMPH-3, and TRIUMPH-Outcomes are listed as Active, not recruiting.^7,8,9,10
• Topline availability: Lilly announced TRIUMPH-1 summaries on May 21, 2026, and TRIUMPH-2 and TRIUMPH-3 summaries on July 23, 2026. A sponsor announcement can exist while a registry record is still not Completed.^11,12
• Peer-reviewed publication availability: papers exist for discovery, Phase 1b, and two Phase 2 trials. In the sources reviewed for this page, there is no TRIUMPH-1, TRIUMPH-2, or TRIUMPH-3 publication comparable to those papers.^1,2,3,4

The FDA page on unapproved GLP-1 drugs refers to the U.S. framework, including consumer-marketed retatrutide products. That source is not translated here into a claim about Mexican law.¹⁴

What LY3437943 is

LY3437943 is Eli Lilly’s development code. Later literature uses retatrutide for the same peptide. Coskun and colleagues presented it in Cell Metabolism in 2022 as a triple agonist of the glucagon, GIP, and GLP-1 receptors, from discovery through a clinical proof of concept.¹

The early papers include authors affiliated with Lilly. That affiliation is preserved in the references. It is not used here to dismiss the papers or to treat them as company releases.

Why it is described as a triple agonist

“Triple” summarizes a target profile, not an efficacy ranking. The peptide was characterized for activity at three receptors. What agonism means, and what it does not prove, is in the mechanism page.

• GIP receptor: one of the three activities described in the discovery work.¹
• GLP-1 receptor: the second activity of the same peptide.¹
• Glucagon receptor: the third activity, which distinguishes this profile from a dual GIP and GLP-1 agonist.¹

The number of receptors does not by itself establish a clinical outcome or a preference over other peptides. Profile comparisons are in retatrutide versus tirzepatide and retatrutide versus semaglutide.

Evidence map

The table below organizes the main sources by type. It does not summarize TRIUMPH numerical outcomes. Each row states what that source establishes and how it should not be read.

Timeline

1. 2022

   Discovery and proof of concept

   Peer-reviewed primary research

   Coskun and colleagues publish the characterization of LY3437943 in Cell Metabolism.¹

2. 2022

   Phase 1b in type 2 diabetes

   Peer-reviewed clinical trial

   Urva and colleagues publish a randomized, placebo-controlled Phase 1b trial in The Lancet.²

3. 2023

   Phase 2 obesity

   Peer-reviewed clinical trial

   Jastreboff and colleagues publish a Phase 2 trial in 338 adults in NEJM (NCT04881760).^3,5

4. 2023

   Phase 2 type 2 diabetes

   Peer-reviewed clinical trial

   Rosenstock and colleagues publish a Phase 2 trial in 281 participants in The Lancet (NCT04867785).^4,6

5. 2023–2026

   TRIUMPH Phase 3 program

   Clinical trial registry

   ClinicalTrials.gov lists TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-Outcomes.^7,8,9,10

6. May 2026

   TRIUMPH-1 topline

   Sponsor topline results

   Lilly announces TRIUMPH-1 topline results. That protocol’s registry status is Completed as of this review.^11,7

7. July 2026

   TRIUMPH-2 and TRIUMPH-3 topline

   Sponsor topline results

   Lilly announces TRIUMPH-2 and TRIUMPH-3 topline results. As of this review, both registry records remain Active, not recruiting.^12,8,9

8. 2026

   Investigational status

   Developer information

   No FDA approval. TRIUMPH-Outcomes remains Active, not recruiting, with no outcomes result in the reviewed sources.^13,10

What is published and what is not

Peer-reviewed: the discovery paper, Phase 1b, and both Phase 2 trials. Those sources have visible methods, limitations, and editorial review.^1,2,3,4

Registry: ClinicalTrials.gov describes protocols and statuses. A registry record is not a paper. Active, not recruiting does not contradict a topline release: they describe different things.^8,9

Sponsor topline: the 2026 releases are Lilly’s initial summaries. They are not presented here as if they had already undergone peer review.^11,12

Peptra analytical documentation

The Retatrutida certificate archive documents analytical results associated with Peptra research-material lots. A Peptra COA does not establish that the material was used in Lilly clinical trials, does not demonstrate pharmaceutical equivalence, does not imply FDA approval, and does not indicate suitability for human use.

The guides on how to read a COA and what 99% purity means explain those limits. They are not duplicated here.